Barinthus Biotherapeutics
BRNS
15 hedge funds and large institutions have $42.4M invested in Barinthus Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.29% less ownership
Funds ownership: 14.35% → 14.06% (-0.29%)
30% less capital invested
Capital invested by funds: $60.2M → $42.4M (-$17.8M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$6.85M |
| 2 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
+$1.36M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.23K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$6.31K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$505 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$5.73M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.86M |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
-$630K |
| 4 |
Millennium Management
New York
|
-$597K |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$325K |
BRNS Hedge Fund Activity: Q4 2021 in Review
15 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q4 2021, worth a combined $42.4M — down 30% from $60.2M a quarter earlier.
Fund positioning in BRNS was balanced in Q4 2021: 5 funds opened new positions, 5 closed out, 0 added to existing stakes and 6 trimmed.
The largest buyer was BlueCrest Capital Management, opening a new position worth an estimated $6.85M. The largest seller was Tudor Investment Corp, exiting entirely with an estimated $5.73M sold.
- 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $42.4M of Barinthus Biotherapeutics stock for Q4 2021, down 30% quarter-over-quarter.
- 5 funds opened new Barinthus Biotherapeutics positions in Q4 2021 and 5 closed out, a net change of 0 holders.
- The largest Barinthus Biotherapeutics buyer in Q4 2021 was BlueCrest Capital Management, an estimated $6.85M added.
- The largest Barinthus Biotherapeutics seller in Q4 2021 was Tudor Investment Corp, an estimated $5.73M sold.
Based on aggregated 13F filings for Q4 2021.